Combinatorial delivery of Ribociclib and green tea extract mediated nanostructured lipid carrier for oral delivery for the treatment of breast cancer synchronising in silico, in vitro, and in vivo studies

References

• Sartaj A, Baboota S, Ali J. Nanomedicine: a promising avenue for the development of effective therapy for breast cancer. Curr Cancer Drug Targets. 2020;20(8):603–615.
   PubMed Web of Science ®Google Scholar
• Robey RW, Pluchino KM, Hall MD, et al. Revisiting the role of efflux pumps in multidrug-resistant cancer. Nat Rev Cancer. 2018;18(7):452–464.
   PubMed Web of Science ®Google Scholar
• Nounou MI, ElAmrawy F, Ahmed N, et al. Syed-Sha-Qhattal, H. Breast cancer: Conventional diagnosis and treatment modalities and recent patents and technologies. Breast Cancer (Auckl). 2015;9s2:BCBCR.S29420.
   Google Scholar
• Hortobagyi GN. Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial. Breast Cancer Res. 2018;20(1):123–134.
   PubMedGoogle Scholar
• Hamilton E, Infante JR. Targeting CDK4/6 in patients with cancer. Cancer Treat Rev. 2016;45:129–138.
   PubMed Web of Science ®Google Scholar
• Rascon K, Flajc G, De Angelis C, et al. Ribociclib in HR+/HER2 – Advanced or metastatic breast cancer patients. Ann Pharmacother. 2019;53(5):501–509.
   PubMed Web of Science ®Google Scholar
• Sartaj A, Baboota S, Ali J. Assessment of combination approaches of phytoconstituents with chemotherapy for the treatment of breast cancer: a systematic review. Curr Pharm Des. 2021;27(45):4630–4648.
   PubMed Web of Science ®Google Scholar
• Huang YJ, Wang KL, Chen HY, et al. Protective effects of epigallocatechin gallate (EGCG) on endometrial, breast, and ovarian cancers. Biomolecules. 2020;10(11):1481–1419.
   PubMed Web of Science ®Google Scholar
• Zhu M, Chen Y, Li RC. Oral absorption and bioavailability of tea catechins. Planta Med. 2000;66(5):444–447.
   PubMed Web of Science ®Google Scholar
• Din FU, Aman W, Ullah I, et al. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomed. 2017;12:7291–7309.
   PubMed Web of Science ®Google Scholar
• Fei Z, Yoosefian M. Design and development of polymeric micelles as nanocarriers for anti-cancer ribociclib drug. J Mol Liq. 2021;329:115574.
   Web of Science ®Google Scholar
• Sartaj A, Biswas L, Verma AK, et al. Ribociclib nanostructured lipid carrier aimed for breast cancer: Formulation optimization, attenuating in vitro specification, and in vivo scrutinization. Biomed Res Int. 2022;2022:6009309.
   PubMed Web of Science ®Google Scholar
• Khan S, Baboota S, Ali J, et al. Nanostructured lipid carriers: an emerging platform for improving oral bioavailability of lipophilic drugs. Int J Pharm Investig. 2015;5(4):182–191.
   PubMed Web of Science ®Google Scholar
• Mustaqeem Abdullah M, Siddiqui NA, Mothana RA, et al. Design, in-silico study and biological evaluation of newly synthesized 3-chlorobenzofuran congeners as antitubercular agents. Arab J Chem. 2021;14(4):103034.
   Web of Science ®Google Scholar
• Haider MR, Ahmad K, Siddiqui N, et al. Novel 9-(2-(1-arylethylidene)hydrazinyl)acridine derivatives: Target topoisomerase 1 and growth inhibition of HeLa cancer cells. Bioorg Chem. 2019;88:102962.
   PubMed Web of Science ®Google Scholar
• Pagadala NS, Syed K, Tuszynski J. Software for molecular docking: a review. Biophys Rev. 2017;9(2):91–102.
   PubMedGoogle Scholar
• Marinelli O, Romagnoli E, Maggi F, et al. Exploring treatment with ribociclib alone or in sequence/combination with everolimus in ER + HER2 – Rb wild-type and knock-down in breast cancer cell lines. BMC Cancer. 2020;20(1):1119–1132.
   PubMed Web of Science ®Google Scholar
• Liu S m, Ou S y, Huang H. Hua green tea polyphenols induce cell death in breast cancer MCF-7 cells through induction of cell cycle arrest and mitochondrial-mediated apoptosis. J Zhejiang Univ Sci B. 2017;18(2):89–98.
   PubMed Web of Science ®Google Scholar
• Chou TC. The combination index (CI < 1) as the definition of synergism and of synergy claims. Synergy. 2018;7:49–50.
   Google Scholar
• Zheng G, Zheng M, Yang B, et al. Improving breast cancer therapy using doxorubicin loaded solid lipid nanoparticles: synthesis of a novel arginine-glycine-aspartic tripeptide conjugated, pH sensitive lipid and evaluation of the nanomedicine in vitro and in vivo. Biomed Pharmacother. 2019;116:109006.[31152925.
   PubMed Web of Science ®Google Scholar
• Figueroa D, Asaduzzaman M, Young F. Real time monitoring and quantification of reactive oxygen species in breast cancer cell line MCF-7 by 2’,7’-dichlorofluorescin diacetate (DCFDA) assay. J Pharmacol Toxicol Methods. 2018;94(Pt 1):26–33.
   PubMed Web of Science ®Google Scholar
• Kakkar P, Das B, Viswanathan PA. Modified spectrophotometric assay of superoxide dismutase, 1984.
   Google Scholar
• Kepinska M, Kizek R, Milnerowicz H. Metallothionein and superoxide dismutase—antioxidative protein status in fullerene-doxorubicin delivery to MCF-7 human breast cancer cells. IJMS. 2018;19(10):3253.
   Google Scholar
• Khan AA, Mudassir J, Akhtar S, et al. Freeze-dried lopinavir-loaded nanostructured lipid carriers for enhanced cellular uptake and bioavailability: Statistical optimization, in vitro and in vivo evaluations. Pharmaceutics. 2019;11(2):97.
   Web of Science ®Google Scholar
• González-Mira E, Nikolić S, García ML, et al. Potential use of nanostructured lipid carriers for topical delivery of flurbiprofen. J Pharm Sci. 2011;100(1):242–251.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Gao F, Bu H, et al. Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats. Nanomed Nanotechnol Biol Med. 2012;8:740–747.
   PubMed Web of Science ®Google Scholar
• Luo Q, Zhao J, Zhang X, et al. Nanostructured lipid carrier (NLC) coated with chitosan oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm. 2011;403:185–191.
   PubMed Web of Science ®Google Scholar
• Innes A, Farrell AM, Burden RP, et al. Complement activation by cellulosic dialysis membranes. J Clin Pathol. 1994;47(2):155–158.
   PubMed Web of Science ®Google Scholar
• Sahibzada MUK, Sadiq A, Khan S, et al. Fabrication, characterization and in vitro evaluation of silibinin nanoparticles: an attempt to enhance its oral bioavailability. Drug Des Devel Ther. 2017;11:1453–1464.
   PubMed Web of Science ®Google Scholar
• Salome AC, Godswill CO, Ikechukwu IO. Kinetics and mechanisms of drug release from swellable and non swellable matrices: a review. Res J Pharm Biol Chem Sci. 2013;4:97–103.
   Google Scholar
• Liu Y, Wang L, Zhao Y, et al. Nanostructured lipid carriers versus microemulsions for delivery of the poorly water-soluble drug luteolin. Int J Pharm. 2014;476(1-2):169–177.
   PubMed Web of Science ®Google Scholar
• Cruz Silva MM, Madeira VMC, Almeida LM, et al. Hemolysis of human erythrocytes induced by tamoxifen is related to disruption of membrane structure. Biochim Biophys Acta – Biomembr. 2000;1464(1):49–61.
   Web of Science ®Google Scholar
• Attari Z, Bhandari A, Jagadish PC, et al. Enhanced ex vivo intestinal absorption of olmesartan medoxomil nanosuspension: Preparation by combinative technology. Saudi Pharm J. 2016;24:57–63.
   PubMed Web of Science ®Google Scholar
• Nagaich U, Gulati N. Nanostructured lipid carriers (NLC) based controlled release topical gel of clobetasol propionate: design and in vivo characterization. Drug Deliv Transl Res. 2016;6(3):289–298.
   PubMed Web of Science ®Google Scholar
• Safwat MA, Soliman GM, Sayed D, et al. Fluorouracil-Loaded gold nanoparticles for the treatment of skin cancer: development, in vitro characterization, and in vivo evaluation in a mouse skin cancer xenograft model. Mol Pharm. 2018;15(6):2194–2205.
   PubMedGoogle Scholar
• Singh A, Neupane YR, Mangla B, et al. Nanostructured lipid carriers for oral bioavailability enhancement of exemestane: Formulation design, in vitro, ex vivo, and in vivo studies. J Pharm Sci. 2019;108(10):3382–3395.
   PubMed Web of Science ®Google Scholar
• Izham MNM, Hussin Y, Rahim NFC, et al. Physicochemical characterization, cytotoxic effect and toxicity evaluation of nanostructured lipid carrier loaded with eucalyptol. BMC Complement Med Ther. 2021;21:1–17.
   PubMedGoogle Scholar
• Nabi B, Rehman S, Aggarwal S, et al. Quality by design adapted chemically engineered lipid architectonics for HIV therapeutics and intervention: contriving of formulation, appraising the in vitro parameters and in vivo solubilization potential. AAPS PharmSciTech. 2020;21(7):261.
   PubMed Web of Science ®Google Scholar
• Baker SJ, Reddy EP. CDK4: a key player in the cell cycle, development, and cancer. Genes Cancer. 2012;3:658–669
   PubMedGoogle Scholar
• Hassan N, Singh M, Sulaiman S, et al. Molecular docking-guided ungual drug-delivery design for amelioration of onychomycosis. ACS Omega. 2019;4(5):9583–9592.
   PubMed Web of Science ®Google Scholar
• Jain AK, Mishra K, Thareja S. In silico docking of anti cancerous drugs with β-Cyclodextrin polymer as a prominent approach to improve the bioavailability. Anticancer Agents Med Chem. 2021;21(10):1275–1283.
   PubMedGoogle Scholar
• Shen Y, Du Y, Zhang Y, et al. Synergistic effects of combined treatment with simvastatin and exemestane on MCF-7 human breast cancer cells. Mol Med Rep. 2015;12(1):456–462.
   PubMed Web of Science ®Google Scholar
• Park HK, Lee JE, Lim J, et al. Combination treatment with doxorubicin and gamitrinib synergistically augments anticancer activity through enhanced activation of bim. BMC Cancer. 2014;14:431–439.
   PubMed Web of Science ®Google Scholar
• Cao C, Wang Q, Liu Y. Lung cancer combination therapy: doxorubicin and & beta-elemene co-loaded, pH-sensitive nanostructured lipid carriers. Drug Des Devel Ther. 2019;13:1087–1098.
   PubMed Web of Science ®Google Scholar
• Rangaraj N, Pailla SR, Shah S, et al. QbD aided development of ibrutinib-loaded nanostructured lipid carriers aimed for lymphatic targeting: evaluation using chylomicron flow blocking approach. Drug Deliv Transl Res. 2020;10(5):1476–1494.
   PubMed Web of Science ®Google Scholar
• Cavalcanti SMT, Nunes C, Lima SAC, et al. Multiple lipid nanoparticles (MLN), a new generation of lipid nanoparticles for drug delivery systems: Lamivudine-MLN experimental design. Pharm Res. 2017;34(6):1204–1216.
   PubMed Web of Science ®Google Scholar
• Rathod VR, Shah DA, Dave RH. Systematic implementation of quality-by-design (QbD) to develop NSAID-loaded nanostructured lipid carriers for ocular application: preformulation screening studies and statistical hybrid-design for optimization of variables. Drug Dev Ind Pharm. 2020;46(3):443–455.
   PubMed Web of Science ®Google Scholar
• Pathak P, Nagarsenker M. Formulation and evaluation of lidocaine lipid nanosystems for dermal delivery. AAPS PharmSciTech. 2009;10(3):985–992.
   PubMed Web of Science ®Google Scholar
• Shtay R, Tan CP, Schwarz K. Development and characterization of solid lipid nanoparticles (SLNs) made of cocoa butter: a factorial design study. J Food Eng. 2018;231:30–41.
   Web of Science ®Google Scholar
• Noroozi M, Radiman S, Zakaria A. Influence of sonication on the stability and thermal properties of alnanofluids. J Nanomater. 2014;2014:1–10.
   Web of Science ®Google Scholar
• Ahad A, Aqil M, Kohli K, et al. Formulation and optimization of nanotransfersomes using experimental design technique for accentuated transdermal delivery of valsartan. Nanomedicine. 2012;8(2):237–249.
   PubMed Web of Science ®Google Scholar
• Subedi RK, Kang KW, Choi HK. Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin. Eur J Pharm Sci. 2009;37(3-4):508–513.
   PubMed Web of Science ®Google Scholar
• Li S, Chen L, Wang G, et al. Anti-ICAM-1 antibody-modified nanostructured lipid carriers: a pulmonary vascular endothelium-targeted device for acute lung injury therapy. J Nanobiotechnol. 2018;16:105–119.
   PubMed Web of Science ®Google Scholar
• Ding X, Xu X, Zhao Y, et al. Tumor targeted nanostructured lipid carrier co-delivering paclitaxel and indocyanine green for laser triggered synergetic therapy of cancer. RSC Adv. 2017;7(56):35086–35095.
   Web of Science ®Google Scholar
• MARKLUND S, MARKLUND G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem. 1974;47(3):469–474.
   PubMedGoogle Scholar
• Zhong P, Chen X, Guo R, et al. Folic Acid-Modified nanoerythrocyte for codelivery of paclitaxel and tariquidar to overcome breast cancer multidrug resistance. Mol Pharmaceutics. 2020;17(4):1114–1126.
   PubMed Web of Science ®Google Scholar
• Uprit S, Kumar Sahu R, Roy A, et al. Preparation and characterization of minoxidil loaded nanostructured lipid carrier gel for effective treatment of alopecia. Saudi Pharm J. 2013;21(4):379–385.
   PubMed Web of Science ®Google Scholar
• Baboota S, Ali J. In vitro appraisals and ex vivo permeation prospect of chitosan nanoparticles designed for schizophrenia to intensify nasal delivery. Polym Bull. 2021;79(4):2263–2223.
   Web of Science ®Google Scholar
• Yang G, Wu F, Chen M, et al. Formulation design, characterization, and in vitro and in vivo evaluation of nanostructured lipid carriers containing a bile salt for oral delivery of gypenosides. Int J Nanomed. 2019;14:2267–2280.
   PubMed Web of Science ®Google Scholar
• Abosabaa SA, Arafa MG, ElMeshad AN. Hybrid chitosan-lipid nanoparticles of green tea extract as natural anti-cellulite agent with superior in vivo potency: full synthesis and analysis. Drug Deliv. 2021;28(1):2160–2176.
   PubMed Web of Science ®Google Scholar
• Rehman S, Nabi B, Sanjula B, et al. Tailoring lipid nanoconstructs for the oral delivery of paliperidone: Formulation, optimization and in vitro evaluation. Chem Phys Lipids. 2021;234:105005.
   PubMed Web of Science ®Google Scholar
• Khan S, Shaharyar M, Fazil M, et al. Tacrolimus-loaded nanostructured lipid carriers for oral delivery-in vivo bioavailability enhancement. Eur J Pharm Biopharm. 2016;109:149–157.
   PubMed Web of Science ®Google Scholar
• Yallapu MM, Ebeling MC, Chauhan N, et al. Ebeling; chauhan; jaggi interaction of curcumin nanoformulations with human plasma proteins and erythrocytes. Int J Nanomed. 2011;6:2779–2790.
   PubMed Web of Science ®Google Scholar
• Wu L, Zhao L, Su X, et al. Repaglinide-loaded nanostructured lipid carriers with different particle sizes for improving oral absorption: preparation, characterization, pharmacokinetics, and in situ intestinal perfusion. Drug Deliv. 2020;27(1):400–409.
   PubMed Web of Science ®Google Scholar
• Soni K, Rizwanullah M, Kohli K. Development and optimization of sulforaphane-loaded nanostructured lipid carriers by the Box-Behnken design for improved oral efficacy against cancer: in vitro, ex vivo and in vivo assessments. Artif Cells Nanomed Biotechnol. 2018;46(sup1):15–31.
   PubMed Web of Science ®Google Scholar
• Gulturk I, Yilmaz M, Ozmen A, et al. Ribociclib induced acute kidney injury: a case report. J Oncol Pharm Pract. 2021;27(8):2023–2026.
   PubMed Web of Science ®Google Scholar
• LiverTox: Clinical and research information on drug-induced liver injury. React Wkly. 2018;1891:259–259.
   Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line therapy for HR-Positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–1748.
   PubMed Web of Science ®Google Scholar
• Alam T, Pandit J, Vohora D, et al. Optimization of nanostructured lipid carriers of lamotrigine for brain delivery: in vitro characterization and in vivo efficacy in epilepsy. Expert Opin Drug Deliv. 2015;12(2):181–194.
   PubMed Web of Science ®Google Scholar